Age-related macular degeneration is an increasingly important public health issue
due to ageing populations and increased longevity. Age-related macular degeneration
affects individuals older than 55 years and threatens high-acuity central vision required
for important tasks such as reading, driving, and recognising faces. Advances in retinal
imaging have identified biomarkers of progression to late age-related macular degeneration.
New treatments for neovascular age-related macular degeneration offer potentially
longer-lasting effects, and progress is being made towards a treatment for atrophic
late age-related macular degeneration.